Pharm Exec's latest annual listing of the top biopharma players paints a stable picture of performance for the usual placeholders, but change and disruption to current business models could upend positioning in the years ahead.

Fosun International Ltd.’s health-care business and Shanghai Pharmaceuticals Holding Co. are among bidders for a stake in U.S. specialty drugmaker Arbor Pharmaceuticals LLC, according to people with knowledge of the matter.

New, Non-Invasive Method May Help with Diagnosis

Samsung Bioepis Co., Ltd. announced today – August 21, 2017 –  that it has entered into a strategic collaboration agreement with Takeda Pharmaceutical Company Limited to jointly fund and co-develop multiple novel biologic therapies in unmet disease areas. The two companies will immediately begin working on the program’s first therapeutic candidate, TAK-671, which is intended to treat severe acute pancreatitis.